ASCO 2023 | What are the latest updates in non-G12C KRAS allele-specific inhibition?

KRAS mutations occur in approximately 30% of non-small cell lung cancer (NSCLC) cases, with KRAS G12C mutations being the most common. Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, describes developments in non-KRAS G12C inhibitors such as MRTX1133, a G12D inhibitor. RAS(ON) inhibitors such as RMC-6236 are additionally in development. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.